CTOs on the Move

Phathom Pharmaceuticals

www.phathompharma.com

 
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Phathom Pharmaceuticals raised $50M on 05/15/2019
Phathom Pharmaceuticals raised $90M on 05/15/2019

Similar Companies

ROSE LifeScience

Cultivation. Commercialization. Logistics. Yes, we`re here to make your life and work happier, and it starts with remarkable cannabis. It continues with business-ready services which help simplify the regulated world. From our proud home in Huntingdon, our family of marketers, growers and industry leaders at ROSE LifeScience are making cannabis thrive in Québec — for our customers, partners, communities and (especially) for you. Happiness is indeed our business. More importantly, it`s the reason why we do business.

EIP Pharma

EIP Pharma is a private, clinical-stage therapeutics company focused on CNS disorders headquartered in Cambridge, Mass. EIP Pharma was launched in 2014 by R&D executives from the pharmaceutical and biotech industry who believed that emerging science supported exploring neflamapimod in Alzheimer’s disease.

Cardiocore Lab, Inc.

Cardiocore Lab, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Amolyt Pharma

Amolyt Pharma is building on its team`s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma`s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.

Process Control Solutions

Process Control Solutions is a Northborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.